These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 21162698)

  • 21. P-glycoprotein, CYP3A, and plasma carboxylesterase determine brain and blood disposition of the mTOR Inhibitor everolimus (Afinitor) in mice.
    Tang SC; Sparidans RW; Cheung KL; Fukami T; Durmus S; Wagenaar E; Yokoi T; van Vlijmen BJ; Beijnen JH; Schinkel AH
    Clin Cancer Res; 2014 Jun; 20(12):3133-45. PubMed ID: 24727322
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efavirenz does not interact with the ABCB1 transporter at the blood-brain barrier.
    Dirson G; Fernandez C; Hindlet P; Roux F; German-Fattal M; Gimenez F; Farinotti R
    Pharm Res; 2006 Jul; 23(7):1525-32. PubMed ID: 16779703
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Kinetic analysis of the cooperation of P-glycoprotein (P-gp/Abcb1) and breast cancer resistance protein (Bcrp/Abcg2) in limiting the brain and testis penetration of erlotinib, flavopiridol, and mitoxantrone.
    Kodaira H; Kusuhara H; Ushiki J; Fuse E; Sugiyama Y
    J Pharmacol Exp Ther; 2010 Jun; 333(3):788-96. PubMed ID: 20304939
    [TBL] [Abstract][Full Text] [Related]  

  • 24. P-glycoprotein (MDR1/ABCB1) and Breast Cancer Resistance Protein (BCRP/ABCG2) affect brain accumulation and intestinal disposition of encorafenib in mice.
    Wang J; Gan C; Sparidans RW; Wagenaar E; van Hoppe S; Beijnen JH; Schinkel AH
    Pharmacol Res; 2018 Mar; 129():414-423. PubMed ID: 29155017
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Abcb1a and Abcb1b expression in senescence-accelerated mouse (SAM).
    Wu B; Ueno M; Kusaka T; Onodera M; Huang CL; Hosomi N; Kanenishi K; Sakamoto H
    Neurosci Lett; 2009 May; 456(1):34-8. PubMed ID: 19429129
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Eribulin mesylate for the treatment of breast cancer.
    Cigler T; Vahdat LT
    Expert Opin Pharmacother; 2010 Jun; 11(9):1587-93. PubMed ID: 20450446
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Increased oral availability and brain accumulation of the ALK inhibitor crizotinib by coadministration of the P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) inhibitor elacridar.
    Tang SC; Nguyen LN; Sparidans RW; Wagenaar E; Beijnen JH; Schinkel AH
    Int J Cancer; 2014 Mar; 134(6):1484-94. PubMed ID: 24037730
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of Rolapitant Administered Intravenously or Orally on the Pharmacokinetics of Digoxin (P-glycoprotein Substrate) and Sulfasalazine (Breast Cancer Resistance Protein Substrate) in Healthy Volunteers.
    Wang X; Zhang ZY; Arora S; Hughes L; Wang J; Powers D; Christensen J; Lu S; Kansra V
    J Clin Pharmacol; 2018 Feb; 58(2):202-211. PubMed ID: 28906558
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of glucocorticoids on regulation of placental multidrug resistance phosphoglycoprotein (P-gp) in the mouse.
    Petropoulos S; Gibb W; Matthews SG
    Placenta; 2010 Sep; 31(9):803-10. PubMed ID: 20655586
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Developmental expression of multidrug resistance phosphoglycoprotein (P-gp) in the mouse fetal brain and glucocorticoid regulation.
    Petropoulos S; Gibb W; Matthews SG
    Brain Res; 2010 Oct; 1357():9-18. PubMed ID: 20709040
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Differential selectivity of efflux transporter inhibitors in Caco-2 and MDCK-MDR1 monolayers: a strategy to assess the interaction of a new chemical entity with P-gp, BCRP, and MRP2.
    Mease K; Sane R; Podila L; Taub ME
    J Pharm Sci; 2012 May; 101(5):1888-97. PubMed ID: 22359351
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The anthelminthic agent albendazole does not interact with p-glycoprotein.
    Merino G; Alvarez AI; Prieto JG; Kim RB
    Drug Metab Dispos; 2002 Apr; 30(4):365-9. PubMed ID: 11901088
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Inhibition of P-glycoprotein-mediated efflux of digoxin and its metabolites by macrolide antibiotics.
    Hughes J; Crowe A
    J Pharmacol Sci; 2010; 113(4):315-24. PubMed ID: 20724802
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Ex vivo and in vivo investigations of the effects of extracts of Vernonia amygdalina, Carica papaya and Tapinanthus sessilifolius on digoxin transport and pharmacokinetics: assessing the significance on rat intestinal P-glycoprotein efflux.
    Oga EF; Sekine S; Horie T
    Drug Metab Pharmacokinet; 2013; 28(4):314-20. PubMed ID: 23291634
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Eribulin shows high concentration and long retention in xenograft tumor tissues.
    Sugawara M; Condon K; Liang E; DesJardins C; Schuck E; Kusano K; Lai WG
    Cancer Chemother Pharmacol; 2017 Aug; 80(2):377-384. PubMed ID: 28664226
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Characterisation of cerivastatin as a P-glycoprotein substrate: studies in P-glycoprotein-expressing cell monolayers and mdr1a/b knock-out mice.
    Kivistö KT; Zukunft J; Hofmann U; Niemi M; Rekersbrink S; Schneider S; Luippold G; Schwab M; Eichelbaum M; Fromm MF
    Naunyn Schmiedebergs Arch Pharmacol; 2004 Aug; 370(2):124-30. PubMed ID: 15322734
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Oleic acid increases uptake and decreases the P-gp-mediated efflux of the veterinary anthelmintic Ivermectin.
    Houshaymi B; Nasreddine N; Kedees M; Soayfane Z
    Drug Res (Stuttg); 2019 Feb; 69(3):173-180. PubMed ID: 30103215
    [TBL] [Abstract][Full Text] [Related]  

  • 38. P-glycoprotein-mediated active efflux of the anti-HIV1 nucleoside abacavir limits cellular accumulation and brain distribution.
    Shaik N; Giri N; Pan G; Elmquist WF
    Drug Metab Dispos; 2007 Nov; 35(11):2076-85. PubMed ID: 17709369
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Commonly used surfactant, Tween 80, improves absorption of P-glycoprotein substrate, digoxin, in rats.
    Zhang H; Yao M; Morrison RA; Chong S
    Arch Pharm Res; 2003 Sep; 26(9):768-72. PubMed ID: 14560928
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Novel second generation analogs of eribulin. Part I: Compounds containing a lipophilic C32 side chain overcome P-glycoprotein susceptibility.
    Narayan S; Carlson EM; Cheng H; Du H; Hu Y; Jiang Y; Lewis BM; Seletsky BM; Tendyke K; Zhang H; Zheng W; Littlefield BA; Towle MJ; Yu MJ
    Bioorg Med Chem Lett; 2011 Mar; 21(6):1630-3. PubMed ID: 21324686
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.